Short answer
According to the text, the effects of GLP-1 agonists on eye health are still being studied. A serious effect is not expected in most people, but those with diabetic retinopathy, vision loss in one eye or a history of optic neuropathy are in the risk group. An eye examination before starting treatment is advised for them.
GLP-1 agonists are drugs that have been widely used in recent years for both diabetes and weight loss. Although they are effective in lowering blood sugar, their effects on eye health are still being researched. For this reason, some risk groups need to be careful.
Diabetes and the Risk of Retinopathy
In people with diabetes, a rapid drop in blood sugar may adversely affect the course of diabetic retinopathy. Especially for patients who already have retinopathy, these changes may pose a risk even if temporary.
Potential Effects on the Optic Nerve and Eye Circulation
In scientific studies, some risks related to the circulation of the optic nerve have been discussed with GLP-1 agonists. For this reason, people who have lost vision in one eye or have previously had optic neuropathy should have an eye examination before using these drugs.
Who Should Be More Careful?
-
Individuals with diabetes
-
Patients who have lost vision in one eye
-
People who have previously had optic neuropathy
Patients in this group must be checked by a physician before starting GLP-1 agonist treatment.
Follow-up and Precautions
-
A detailed eye examination before treatment
-
Blood sugar monitoring during regular eye check-ups
-
Treatment under physician supervision for patients at risk of diabetic retinopathy or optic nerve problems
These precautions allow possible side effects to be detected early and help protect visual health.
Frequently Asked Questions
1. Does using GLP-1 agonists affect vision?
For most people there is no serious effect; however, those with diabetic retinopathy or a history of optic nerve problems are at risk.
2. Can every person with diabetes use this drug?
Most patients with diabetes can use it safely; however, if there is vision loss in one eye or a history of optic neuropathy, a physician's check is required.
3. How often should eye check-ups be done during treatment?
The physician determines this according to the patient's condition and risk factors; ultrasound, a vision test or a retinal examination at regular intervals is generally recommended.
4. Might the drug need to be stopped?
Only if a serious risk to eye health arises will the physician reassess the treatment plan. In most cases, regular follow-up is sufficient.
5. Does this information replace diagnosis or treatment?
No. The content is for informational purposes only. For every patient, the treatment and follow-up plan must be determined by a physician.
Scientific references
- Natividade GR, Spiazzi BF, Baumgarten MW, et al.. Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis. JAMA Ophthalmol. 2025. PMID: 40810985
- Amini A, Hamann S, Larsen M. Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association. Acta Ophthalmol. 2025. PMID: 40055951
- Nadeem N, Al Issa RM, Shah A, et al.. In the Eye of Controversy: A Deeper Look Into the Impact of Glucagon-like Peptide-1 Receptor Agonists on Diabetic Retinopathy and Nonarteritic Anterior Ischemic Optic Neuropathy. Can J Diabetes. 2025. PMID: 40712696



